Morning, Marco. The federal page you were told to stop trusting finally updated — and it
moved by more than three thousand cases in a single jump, which tells you something about
how the counting works. Also: a 21,000-woman study that will land in a family meeting
before it lands in a guideline, and a fight over who gets your ER's patient names.
Coffee, then sleep.
A · Top Stories
Three items. All moved in the last 48 hours.
Update: the cyclospora page caught up — and it jumped from 6,358 to 9,481 cases in one revision
Yesterday the outbreak page had been frozen since August 5 while the outbreak wasn't.
It has now moved: the multistate iceberg-lettuce outbreak stands at
9,481 illnesses across 17 states, with at least
398 hospitalizations and two deaths, both in Michigan. That's an
increase of more than 3,100 cases in a single update. Maine and Massachusetts are the
newly added states, and FDA has begun onsite inspection and sampling at Taylor Farms de
México. The most useful number in the release is the one nobody headlines:
last illness onset August 3.
Why it matters to you. The last-onset date is the clinical line.
Product with any plausible shelf life is long gone, so a new watery diarrhea presenting
this weekend is very unlikely to belong to this cluster — but the wider surveillance
number is the one that should keep the test on your list. CDC has logged roughly
13,900 lab-confirmed domestic cyclosporiasis cases since May 1 against
about 1,180 in the same window last year. That is a season, not an outbreak, and it
doesn't end when the lettuce does.
Suggested action: you can put the federal page back in rotation as a
denominator — but note how it updates. It caught up in a lump, not a stream. If you
quote a number at a group meeting, say the date it was published, not "currently."
CDC investigation update ·
FDA outbreak page ·
Food Safety News, Aug 13
Estrogen-only menopausal hormone therapy linked to 39% lower odds of dementia — with autopsy data behind it
Stanford investigators published in Neurology on August 12 an analysis of
21,462 women drawn from national datasets, and the coverage caught up
over the last 48 hours. Women who had used estrogen-only menopausal
hormone therapy had 39% lower odds of a clinical dementia diagnosis
and 35% lower odds of Alzheimer's pathology at autopsy, with biomarker
profiles consistent with less amyloid accumulation. They also performed better on
memory testing and functional independence measures. The autopsy arm is what makes this
more than another observational hormone-therapy headline — the association survives when
you look at brains rather than billing codes.
Why it matters to you. Not because it changes anything you prescribe —
it doesn't, and the authors say so plainly. It matters because this is exactly the study
that reaches a family before it reaches a guideline. You will get the question from the
daughter of an 82-year-old with delirium on top of baseline cognitive impairment: "she
was taken off estrogen in 2003, did that cause this?" The honest answer has three parts:
observational design, historical treatment patterns that don't map onto today's
prescribing, and estrogen-only regimens (i.e., post-hysterectomy women), which
is a different population from combined therapy.
Suggested action: bank one sentence for the family conversation —
"this was an association in women who were treated decades ago, and the researchers
themselves say it can't show cause." Saying it before the family Googles it is worth
ten minutes of your night.
Stanford Medicine ·
Medscape ·
Scientific American
KFF: about $60B in federal Medicaid hospital payments across 37 states sits above the new OBBBA caps
A KFF analysis circulating this week puts numbers on the state directed payment (SDP)
limits in the 2025 reconciliation law. Previously states could direct managed-care plans
to pay hospitals up to average commercial rates; the new limits cap
those payments at or near Medicare levels. KFF estimates roughly
$60 billion in federal Medicaid spending across 37 states and
D.C. would exceed the new ceilings once fully implemented. Eight states account
for half of the exposure: California ($7.4B), Illinois ($4.0B), Kentucky ($3.9B), Texas
($3.5B), North Carolina ($3.4B), Louisiana ($3.3B), Arizona ($3.0B), Michigan ($2.6B).
Why it matters to you. Third squeeze in three weeks pointing at the
same place. You've already got the statutory site-neutral cut in the CY2027 OPPS rule
(comments close August 31) and the FY2027 IPPS rule effective October 1. SDP caps are
the Medicaid-side version. None of these change a single order you write — they change
what your hospital can afford to keep open, which shows up in your world as bed
availability, case-management staffing, and which post-discharge clinics still take
Medicaid in ninety days.
Suggested action: when the site-neutral comment letter goes around
before August 31, this is the second paragraph. Not "payment is going down" — but that
three separate mechanisms hit the same transitions-of-care infrastructure on overlapping
timelines, and nobody has modeled them together.
KFF analysis ·
HFMA
B · The Debate
One topic, both sides, no verdict.
Should a federal safety agency be able to pull identifiable emergency-department records on every patient?
Why it's live right now: the Consumer Product Safety Commission is
rebuilding the National Electronic Injury Surveillance System — "NEISS-R" — expanding
from roughly 70 hospitals in 36 states to 100 hospitals in all 50, and from about
400,000 records reviewed a year to roughly 2 million, routed through a contractor,
Konza Health, on a $15.9M award. Reporting in late July established that CPSC asked
hospitals for names, addresses and diagnoses for all ED patients, not just
product-related injuries. On August 12 the American Hospital Association
filed a comment letter asking the agency to pause and scale the request back — which is
what moved this from a reporting story to a live policy fight.
The case for
Injury surveillance built on hand-abstracted, de-identified summaries from seventy
hospitals is a 1970s instrument being used to police a 2020s consumer market. Acting
CPSC Chairman Peter Feldman has framed the rebuild as the agency
"investing in AI-enabled workflows that improve the quality and quantity of injury
surveillance data," with the digital infrastructure to handle a much larger volume of
electronic health records. The argument underneath: you cannot detect a rare defect —
a battery that ignites, a crib that entraps, a recalled device that keeps injuring
people after the recall — from a 400,000-record sample abstracted by hand, and every
year of undercounting is measured in children. Automated extraction also reduces the
manual handling of sensitive records that the current system depends on, which the
agency argues is a privacy improvement, not a cost.
CPSC on NEISS ·
NEISS 2026 fact sheet
The case against
A product-safety agency asking for every ED patient's name and address is collecting
far past its own mandate — the requested categories include injuries CPSC does not
regulate. The American Hospital Association, in its August 12 letter,
asked CPSC to collect only what is "minimally necessary" for injury surveillance, to
explain how it will comply with data privacy and security law, and to keep hospital
participation voluntary; AHA reports its members are confused about whether
participation is mandatory at all, since CPSC and the contractor have both used that
word. The Consumer Federation of America — not an industry group —
raised the same objection from the consumer side, questioning whether identifiable
personal health data is needed to do the job. Several systems, including Mass General
Brigham, Harborview and Henry Ford Health, have already declined or paused.
AHA, Aug 12 ·
Consumer Federation of America ·
KFF Health News
Where it might land: the unresolved question is whether participation is
mandatory or voluntary — CPSC and Konza have said mandatory, AHA is asking the agency to
say voluntary in writing. That single word decides whether this is a privacy debate or a
compliance deadline.
A page that caught up all at once, a study that will reach a family before it reaches a
guideline, and a Green Lantern show critics like. Sleep well, Marco.